New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
07:00 EDTFMS, DVAFresenius Medical shares should be bought, says Bernstein
Bernstein notes that Fresenius' (FMS) stock has sharply underperformed versus its competitor, DaVita (DVA), since May 2012. But the firm predicts that Fresenius' core U.S. business should outperform that of DaVita going forward. Bernstein adds that it finds Fresenius' business units aside from its U.S. dialysis clinics more attractive than DaVita's businesses other than its U.S. dialysis clinics.
News For FMS;DVA From The Last 14 Days
Check below for free stories on FMS;DVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 27, 2014
15:12 EDTFMS Hospira in talks to acquire Danone medical nutrition business, FT says
French consumer company Danone (DANOY) has been in negotiations to sell its medical nutrition business to Hospira (HSP) in a deal said to value the unit at $5B, says the Financial Times. The deal would also allow for U.S. based Hospira to domicile its tax base in Europe in a tax strategy known as an inversion, added the Financial Times. In prior reports, Nestle (NSRGY) and Fresenius (FMS) have also been mentioned as suitors for the Danone unit. Reference Link
July 21, 2014
10:02 EDTDVAOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:43 EDTDVADaVita downgraded to Market Perform from Outperform at Raymond James
Subscribe for More Information
July 18, 2014
16:05 EDTDVADaVita says CEO of HealthCare Partners subsidiary to step down
DaVita HealthCare Partners announced that HealthCare Partners, or HCP, president and CEO Dr. Craig Samitt is stepping down from HCP effective August 1. Kent Thiry, co-chairman and CEO of DaVita HealthCare Partners, will take over the role of CEO of HCP, working in tandem with the office of Chief Medical Officer.
July 17, 2014
07:00 EDTDVA, FMSFresenius Medical shares should be bought, says Bernstein
Bernstein notes that Fresenius' (FMS) stock has sharply underperformed versus its competitor, DaVita (DVA), since May 2012. But the firm predicts that Fresenius' core U.S. business should outperform that of DaVita going forward. Bernstein adds that it finds Fresenius' business units aside from its U.S. dialysis clinics more attractive than DaVita's businesses other than its U.S. dialysis clinics.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use